Log In
Print
BCIQ
Print
Print this Print this
 

blisibimod (A-623) (formerly AMG 623)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionPeptide fusion protein that antagonizes BLyS (BAFF)
Molecular Target BLyS (BAFF)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today